Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors Paul AndersonJames LouieMichael Broder Invited Commentary Pages: 3 - 9
State-of-the-art disease-modifying osteoarthritis drugs Roland W. MoskowitzMichele Hooper OriginalPaper Pages: 15 - 21
How can one develop disease-modifying drugs in osteoarthritis? Maxime Dougados OriginalPaper Pages: 22 - 28
Considerations in the treatment of early osteoarthritis Senada ArabelovicTimothy E. McAlindon OriginalPaper Pages: 29 - 35
Treatment of metabolic bone disease in patients with chronic renal disease: A perspective for rheumatologists Paul D. Miller OriginalPaper Pages: 53 - 60
Combination therapy for osteoporosis: Considerations and controversy Neil BinkleyDiane Krueger OriginalPaper Pages: 61 - 65